Syncona reports positive findings from investee Freeline

Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, ‘FLT20’, showed encouraging results.